IGC Stock Overview
A clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IGC Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$0.91 |
| 52 Week Low | US$0.25 |
| Beta | 1.28 |
| 11 Month Change | 3.99% |
| 3 Month Change | -3.58% |
| 1 Year Change | 27.58% |
| 33 Year Change | -73.43% |
| 5 Year Change | -56.22% |
| Change since IPO | -99.30% |
Recent News & Updates
Shareholder Returns
| IGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.9% | -3.7% | -1.6% |
| 1Y | 27.6% | 17.2% | 30.8% |
Return vs Industry: IGC exceeded the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: IGC underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| IGC volatility | |
|---|---|
| IGC Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IGC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IGC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 67 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. Fundamentals Summary
| IGC fundamental statistics | |
|---|---|
| Market cap | US$29.14m |
| Earnings (TTM) | -US$13.30m |
| Revenue (TTM) | US$1.06m |
27.4x
P/S Ratio-2.2x
P/E RatioIs IGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGC income statement (TTM) | |
|---|---|
| Revenue | US$1.06m |
| Cost of Revenue | US$421.00k |
| Gross Profit | US$641.00k |
| Other Expenses | US$13.94m |
| Earnings | -US$13.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 60.36% |
| Net Profit Margin | -1,252.64% |
| Debt/Equity Ratio | 1.7% |
How did IGC perform over the long term?
See historical performance and comparison